Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies (Q37471114)

20 August 2017

Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies (English)

1 reference

20 August 2017

1 reference

1 reference

Chloe Tesmoingt

1

1 reference

20 August 2017

Olivier Lidove

2

1 reference

20 August 2017

Axele Reberga

3

1 reference

20 August 2017

Marguerite Thetis

4

1 reference

20 August 2017

Chloe Ackaert

5

1 reference

20 August 2017

Pascale Nicaise

6

1 reference

20 August 2017

Philippe Arnaud

7

1 reference

20 August 2017

Thomas Papo

8

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 November 2009

1 reference

British Journal of Clinical Pharmacology

20 August 2017

1 reference

20 August 2017

68

1 reference

20 August 2017

5

1 reference

20 August 2017

765-769

1 reference

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Long-term safety and efficacy of enzyme replacement therapy for Fabry disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

The pulvinar sign: frequency and clinical correlations in Fabry disease

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Fabry disease: impaired autonomic function.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2791983

Anaphylaxis to muscle relaxants: cross-sensitivity studied by radioimmunoassays compared to intradermal tests in 34 cases

2 September 2018

1 reference

12 December 2020

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

1 reference

12 December 2020

Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme

1 reference

12 December 2020

Fabry disease and treatment with agalsidase alpha: unsuspected cardiac arrhythmia in two heterozygous women. In reference to pharmacovigilance

1 reference

12 December 2020

Immunoquantification of alpha-galactosidase: evaluation for the diagnosis of Fabry disease

1 reference

12 December 2020

Osteopenia and osteoporosis: previously unrecognized manifestations of Fabry disease

1 reference

12 December 2020

10.1111/J.1365-2125.2009.03501.X

Identifiers

DOI

1 reference

20 August 2017

1 reference

20 August 2017

1 reference